Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas
NCT06623201Phase 1Recruiting
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sonidegib and 5-aminolevulinic acid in basal cell carcinoma (BCC). Primary endpoints: Primary efficacy outcome at 180 days and Adverse Events likely related to study drug at 180 days. Started Oct 2024; status: recruiting.
02
Drugs
sonidegib5-aminolevulinic acid
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT06623201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06623201.